Chronic Obstructive Pulmonary Disease

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Jun 10, 2013
popularity not rated yet | comments 0

Latest Spotlight News

War between bacteria and phages benefits humans

In the battle between our immune systems and cholera bacteria, humans may have an unknown ally in bacteria-killing viruses known as phages. In a new study, researchers from Tufts University, Massachusetts ...

Research shows seven-year-olds can think strategically

(Medical Xpress)—A study by Melissa Koenig of the University of Minnesota and colleagues shows that by the time they reach the age of seven, children can think strategically, in an adult manner. The researchers ...

Childhood trauma could lead to adult obesity

Being subjected to abuse during childhood entails a markedly increased risk of developing obesity as an adult. This is the conclusion of a meta-analysis carried out on previous studies, which included a total ...